By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Pierre Fabre Medicament 

Parc Industriel de la Chartreuse

Castres Cedex    81106  France
Phone: 33-0-5-63-71-45-00 Fax:


SEARCH JOBS


Industry
Biotechnology






Company News
The Swiss Federal Institute Of Technology In Lausanne EPFL And Pierre Fabre Medicament (PFM) Join Forces To Study The Use Of Biosensor Chips In The Clinical Development Of Drugs 11/10/2015 11:01:39 AM
Forest Laboratories, Inc. (FRX) and Pierre Fabre Medicament Announce Third Positive Phase III Study for Levomilnacipran in Patients With Major Depressive Disorder 4/26/2012 7:28:32 AM
Forest Laboratories, Inc. (FRX) and Pierre Fabre Medicament Announce Positive Phase III Results For Levomilnacipran in Patients With Major Depressive Disorder 3/7/2012 7:28:59 AM
Pierre Fabre Medicament is Granted Authorization in Australia to Market the Milnacipran JONCIA(R) to Treat Fibromyalgia 11/21/2011 11:56:20 AM
Forest Laboratories, Inc. (FRX), Pierre Fabre Medicament Announce Positive Phase III Results with Levomilnacipran in Patients with Major Depressive Disorder 7/18/2011 6:32:52 AM
Pierre Fabre Medicament And Zambon Sign Commercial Agreement In Germany 2/21/2007 5:14:34 PM
Novacea And Pierre Fabre Medicament Enter Into Partnership For The Development And Commercialization Of Oral Vinorelbine For Oncology10/19/2005 5:12:09 PM
Pierre Fabre Medicament And Merck & Co. (MRK) Sign Oncology Research Partnership And Licensing Agreement10/19/2005 5:11:19 PM
Bristol-Myers Squibb Company (BMY) And Pierre Fabre Medicament Enter Into Agreement To Develop And Commercialize Oncology Treatment Javlor(R) (vinflunine)10/19/2005 5:10:57 PM
Cypress Bioscience Inc., (CYPB) Forest Laboratories, Inc. (FRX) And Pierre Fabre Medicament Announce Development And Marketing Agreement For Milnacipran10/19/2005 5:09:39 PM
//-->